Hengrui showcases oncology research at ESMO 2026 congress
Chinese pharmaceutical firm Hengrui presented 64 research abstracts at the ESMO 2026 congress in Madrid, highlighting its ongoing expansion into global oncology markets.
Hengrui presented 64 research projects at the 2026 European Society for Medical Oncology (ESMO) congress in Madrid. The scale of the data presented illustrates the company's focus on scaling its research and development operations to compete on an international stage.
The presentations covered a range of studies, including clinical trials exploring novel drug combinations and therapeutic approaches to cancer treatment. By showcasing these results at a major European forum, the company seeks to gain broader recognition and validation from the global medical community.
This move comes as Hengrui attempts to pivot from its strong domestic position in China toward a more significant footprint in international markets. Industry observers will continue to monitor the follow-up data from these trials to assess the commercial viability of the company's oncology pipeline.